Optimizing systemic therapy selection in metastatic colorectal cancer

Axel Grothey

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


For metastatic colorectal cancer, many effective agents can be incorporated into multiple lines of therapy across the nearly 3-year continuum of treatment. Emphasis should be on using all the recommended agents, with extended duration of anti-vascular endothelial growth factor treatment, and on identifying patients with any mutation in the RAS pathway. Chemotherapy plus bevacizumab or an epidermal growth factor receptor antibody are both viable options as first-line therapy in patients with RAS wild-Type disease.

Original languageEnglish (US)
Pages (from-to)682-685
Number of pages4
JournalJNCCN Journal of the National Comprehensive Cancer Network
StatePublished - May 1 2015

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Optimizing systemic therapy selection in metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this